Navigation Links
fibrosis in Biological Technology

Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once-Daily INFERGEN(R) with Ribavirin in Hepatitis C Virus Treatment Failures

... interferon-sensitive patients with lower baseline fibrosis scores," stated Dr. Bruce Bacon the lead ... patients with low baseline liver fibrosis scores, the researchers reported in the June 2009 ... with initial therapy Patients with fibrosis scores of F0 to F3 at baseline demonstrated SVRs ...

Phase 3 Cystic Fibrosis Trial Results Presented at European Conference

... III trial of Bronchitol in patients with cystic fibrosis have been presented at the 2009 European Cystic ... Drug Designation and fast track status for cystic fibrosis from the U.S. Food and Drug Administration and ... to be presented at the North American Cystic fibrosis conference in Minneapolis in October. ...

PTC Therapeutics Receives $2.6 Million in Government Grants

... drug status for the treatment of DMD and cystic fibrosis due to nonsense mutations. The FDA has also ... has also been supported by grants from the Cystic fibrosis Foundation Therapeutics Inc. (the nonprofit affiliate of the Cystic fibrosis Foundation), FDA's Office of Orphan Products ...

Study Finds Noninvasive Blood Test for Liver Fibrosis May Alleviate Need for Liver Biopsies for Some Patients with Chronic Hepatitis C

... demonstrates that the Hepascore(TM) liver fibrosis blood-serum test panel may help physicians more accurately diagnose and stage liver fibrosis in patients with chronic hepatitis C (HCV), ... long sought a noninvasive technique for assessing fibrosis without conducting a liver biopsy, a painful ...

Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS

... mortality in patients with idiopathic pulmonary fibrosis (IPF) will be presented in a poster discussion ... IN PATIENTS WITH IDIOPATHIC PULMONARY fibrosis (IPF) POSTER 216: P.W. Noble: THE ... portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. ...

Mpex Pharmaceuticals Names Mark Wiggins Chief Business Officer

... for the prevention of exacerbations in cystic fibrosis (CF) and chronic obstructive pulmonary disease ... of lives for patients suffering from cystic fibrosis or COPD. Exacerbations remain a significant ... of exacerbations in patients with cystic fibrosis and COPD. MP-376 is currently in Phase 2 studies ...

InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF

... pirfenidone in patients with idiopathic pulmonary fibrosis (IPF). The primary endpoint of change in ... 2007. About IPF Idiopathic pulmonary fibrosis (IPF) is a disabling and ultimately fatal disease ... portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. ...

Chronic Lung Disease - Axentis Pharma Attracts Investment Interest

... to cater to unmet medical needs such as cystic fibrosis and other respiratory diseases. In the case ... leads to rapid cell death. About cystic fibrosis Cystic fibrosis is the most common life-threatening hereditary ...

InterMune Reports Third Quarter 2008 Financial Results and Business Highlights

... the first drug approved for idiopathic pulmonary fibrosis (IPF) in any major market in the world. We ... pirfenidone as Pirespa(R) in idiopathic pulmonary fibrosis (IPF). -- InterMune confirmed excellent study ... portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. ...

InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF

... treatment of patients with idiopathic pulmonary fibrosis (IPF) in Japan. Pirfenidone was developed in ... IPF. About IPF Idiopathic pulmonary fibrosis (IPF) is a disabling and ultimately fatal disease ... portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. ...

Transave, Inc. Secures $12.5 Million in New Financing

... aeruginosa, a lung infection common in cystic fibrosis (CF) patients. The improvement in lung function ... The data were presented at the European Cystic fibrosis Society Conference in Prague, Czech Republic. Cystic fibrosis Foundation Therapeutics, the nonprofit affiliate ...

Pigs bred with cystic fibrosis provide model to mimic human disease

... COLUMBIA, Mo. Cystic fibrosis (CF) continues to be a lethal disease for humans ... researcher is producing pigs born with cystic fibrosis that mimic the exact symptoms of a newborn with ... the potential it has to move research on cystic fibrosis forward." ...

40 High-Achieving Students with Cystic Fibrosis Receive $100,000 Total in Higher Education Scholarships From SolvayCARES(SM)

... $100,000 to 40 students living with cystic fibrosis (CF) through its SolvayCARES Scholarship program. ... with a scholarship totaling $10,000. Cystic fibrosis presents extraordinary health burdens for ... are pursuing dreams of higher education. Cystic fibrosis is an inherited chronic disease that affects ...

PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet

... demonstrates activity in nonsense-mutation cystic fibrosis (CF). The data show that treatment with PTC124 ... approximately 10 percent of the cases of cystic fibrosis worldwide. However, in Israel, nonsense mutations ... Vice President of Medical Affairs at the Cystic fibrosis Foundation. "The development of PTC124 fits well ...

Genzyme Corporation and PTC Therapeutics Announce Collaboration on Small Molecule for Genetic Diseases

... dystrophy (DMD), and a phase 2b trial in cystic fibrosis (CF) is expected to begin by the end of this ... trials in nonsense-mutation-mediated cystic fibrosis and in nonsense-mutation-mediated Duchenne ... of PTC124 is supported by grants from the Cystic fibrosis Foundation, the Muscular Dystrophy Association, ...

Cystic Fibrosis - Axentis Pharma Takes Over Patents and Continues Development of Innovative Platform Technology

... screening tool for treatments for cystic fibrosis were transferred today to Swiss biotech company ... by a new approach to the treatment of cystic fibrosis and secured the relevant rights. The technology ... with cystic fibrosis, the protein CFTR (cystic fibrosis conductance regulator) with mutated structure is ...

PTC124 Featured at Third Annual Congress of Myology

... Genetic disorders, such as DMD and cystic fibrosis (CF), are caused by genetic alterations, known as ... muscular dystrophy (DMD) and cystic fibrosis (CF). PTC124 is potentially applicable to a ... the Muscular Dystrophy Association (MDA), Cystic fibrosis Foundation Therapeutics, Inc. (CFFT), Parent ...

Coalition for Pulmonary Fibrosis and American Thoracic Society Continue Research Partnership Through 2010

... The ATS/CPF Partnership Grant for Pulmonary fibrosis was established in 2006. The first grant through ... bleomycin treatment. About Idiopathic Pulmonary fibrosis (IPF) IPF is a lung disorder characterized by a progressive scarring -- known as fibrosis -- and deterioration of the lungs, which slowly ...

Cystic Fibrosis Trial In Children Returns Positive Data

... a Phase II clinical trial in children with cystic fibrosis demonstrated excellent lung function improvement ... People affected by cystic fibrosis typically experience a decline in lung function ... pharmaceutical markets are affected with cystic fibrosis and no products have been approved to ...

Study Confirms Anti-Infective ARIKACE(TM) Effectively Penetrates Mucus and Biofilm, and Kills Pseudomonas, a Bacteria Plaguing Cystic Fibrosis Patients

... for bacteria. This prevents patients with cystic fibrosis (CF) from clearing infections even under ... ). The Cystic fibrosis Foundation provided a $1.7 million award for the clinical program. The Cystic fibrosis Foundation is the leading organization devoted to ...

Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis

... solution for inhalation. Patients with cystic fibrosis (CF) suffer from chronic infections of the lower ... orphan drug designation for MP-376 in cystic fibrosis is an important milestone for the program," ... Development Network (TDN) of the Cystic fibrosis Foundation, the company expects to initiate a ...

Possible New Way to Detect, Monitor Liver Disease Without Painful Liver Biopsy

... to liver biopsy for the early detection of liver fibrosis and cirrhosis, which afflict more than 5 million ... treatment depends on the early detection of fibrosis and cirrhosis. Currently, detection involves a ... very well with a diagnosis of increasing fibrosis and cirrhosis in the new study. "This is a ...

Cystic Fibrosis: License Agreement Boosts Development of Therapy Against Lung Infections

... delivery system for lung infections in Cystic fibrosis patients was signed today. As part of the ... of therapy against lung infections in Cystic fibrosis patients. Under the terms of the agreement ... to the endobronchial sites of infection in Cystic fibrosis patients. This results in prolonged, high local ...

JCI table of contents: Dec. 3, 2007

... lung transplantation. Once the diagnosis of fibrosis is made, a patients chances of survival are very ... organ is likely to play a key role in preventing fibrosis and improving long-term patient survival, ... was not performed. In rejected organs, prior to fibrosis of the trachea being observed, researchers found ...

PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis

... Data Presented at 21st North American Cystic fibrosis Conference Confirm Previous Findings in ... Division Chief, at the 21st North American Cystic fibrosis Conference in Anaheim, California. (Logo: ... reported at last year's North American Cystic fibrosis Conference reproduced by additional investigators ...

GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis

... suite for the integration and analysis of cystic fibrosis data. GeneGo's proprietary software combines ... "We are very pleased to work with Cystic fibrosis Foundation and the academic community which is ... The project will be guided by a Cystic fibrosis Foundation committee with a goal to leverage ...

New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation

... -- Eloxatin(R) has been associated with pulmonary fibrosis ( patients), which may be fatal. The combined ... interstitial lung disease or pulmonary fibrosis -- Eloxatin(R) is associated with two types of ... or sinusoidal alterations, perisinusoidal fibrosis and veno-occlusive lesions. Hepatic vascular ...

BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco

... extended and improved the lives of cystic fibrosis patients," said Dr. Alan Verkman, Professor of Medicine and Physiology and Director of the Cystic fibrosis Research Development Program at the University of ... growing product development pipeline. The cystic fibrosis indication aligns well with our existing product ...

InterMune Reports Second Quarter 2009 Financial Results and Business Highlights

... prescriptions of Actimmune for the treatment of idiopathic pulmonary fibrosis (IPF), which InterMune does not promote. Research and development ... InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio ...

InterMune Reports First Quarter 2009 Financial Results and Business Highlights

... from our Phase 3 CAPACITY program of pirfenidone in idiopathic pulmonary fibrosis (IPF). In April, we reported with Roche and Pharmasset exciting new data ... InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio ...

Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411

... grant funding from the National Institutes of Health (NIH) and Cystic fibrosis Foundation Therapeutics, Inc. (CFFT) For more information, please visit ... America, Europe and Australia. For information about the Cystic fibrosis Foundation, please visit www.cff.org . ...

InterMune Reports Second Quarter 2008 Financial Results and Business Highlights

... prescriptions of Actimmune for the treatment of idiopathic pulmonary fibrosis (IPF), which InterMune does not promote. Revenue from the collaboration ... InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio ...

FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions

... Gadolinium-based contrast agents increase the risk of Nephrogenic Systemic fibrosis in patients with: -- acute or chronic severe renal insufficiency ... resonance imaging (MRI). NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs. Screen all patients for ...

Nektar Receives Patent Covering Pulmonary Targeted Antibiotics

... the prevention and treatment of Pseudomonas aeruginosa pneumonia. Cystic fibrosis patients are susceptible to chronic infection by P. aeruginosa, which is ... remains at the forefront of our fields." About Cystic Fibrosis Cystic fibrosis (CF) is a genetic disease. About 30,000 people in the United States and ...

JCI online early table of contents: March 6, 2008

... EDITOR'S PICK: Genetic manipulation might model cystic fibrosis Cystic fibrosis (CF) is caused by mutations in the gene responsible for making the protein ...

Data show a decline in cystic fibrosis since introduction of prenatal carrier screening

... of Massachusetts has offered universal newborn screening to detect cystic fibrosis (CF) since 1999. Independently, recommendations for nationwide (adult) ... the American College of Medical Genetics. Newborn screening for cystic fibrosis (much like newborn screening for other conditions), a public health ...

InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance

... prescriptions of Actimmune for the treatment of idiopathic pulmonary fibrosis (IPF), which InterMune does not promote. In March 2007, InterMune ... InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio ...

Mpex Pharmaceuticals Names Dr. Jeffery Loutit as Chief Medical Officer

... the treatment of chronic respiratory infections in patients with cystic fibrosis and other serious lung diseases." "In addition, we are eager to use his ... of chronic lung infections due to Pseudomonas aeruginosa in cystic fibrosis patients. The company is also pursuing applications related to its ...

InterMune to Present at Canaccord Adams Conference

... and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with IPF ...

SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights

... Launch Plans - The company is on track to launch three diagnostic products through its CLIA laboratory by the first quarter of 2010 - cystic fibrosis carrier screen (CFTR), RHD and fetal sex determination. The first of these tests - CFTR - is expected to launch this quarter or early next quarter. ...
Other Contents
(Date:11/18/2014)... BOSTON , Nov. 17, 2014   ... HealthCare and EMC collaborate to develop The Partners ... , The Partners Data Lake will allow ... to improve diagnostics, treatment and the lives of ... support research and clinical activities across the Partners ...
(Date:11/18/2014)... YORK , Nov. 18, 2014   ... identity authentication solutions, and MorphoTrust USA ... and services, today announced a strategic partnership to ... enterprise, motor vehicle administration (MVA), airport screening and ... in identity-related solutions, MorphoTrust serves consumers through a ...
(Date:11/12/2014)... , Nov. 12, 2014 Crossmatch™, a leading ... its U.are.U ® fingerprint readers have been deployed ... Central Mexico . The bakery chain ... eliminate payroll issues caused by employees clocking in for ... U.are.U fingerprint readers, Montparnasse relied on paper timecards and ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
(Date:12/20/2014)... December 21, 2014 BambooIndustry.com is ... Recently, the business has announced its bamboo flooring ... the best material from certified suppliers, and offers ... customers worldwide. In the current promotion, all customers ... off, when they say they know BambooIndustry.com from ...
(Date:12/20/2014)... York, NY (PRWEB) December 20, 2014 ... the healthcare sector have benefited the Massage Services ... the discretionary characteristics of industry products, the anticipated 1.0% ... five-year period has provided consumers with the means to ... that have received a massage in a given year ...
(Date:12/20/2014)... print component of Healthy Aging is distributed within today’s ... and an estimated readership of 420,000. The digital component ... and across a network of top news sites and ... campaign, click here . , The publication features ... The Social. Lainey Lui, Melissa Grelo, Traci Melchor, ...
(Date:12/20/2014)... The Doctor’s Office Urgent Care of Paramus, New Jersey ... decade. They’ve treated over 40,000 patients while carrying out ... alternative to the Paramus area. , For 2015, the ... staff of top-notch board certified physicians: Christine Milosis MD, Sandra ... new doctors will work tirelessly to carry out The ...
(Date:12/20/2014)... Atore, Inc, (San Francisco, CA CEO: Masashi ... focused portal on December 17th, 2014. , One ... US and Japan. , MERRY BIRTHDAY SITE : ... , MERRY BIRTHDAY MESSAGE is part of 5 future ... Features, Choose from thousands of stock photos to decorate ...
Breaking Medicine News(10 mins):Health News:Eco-friendy Bamboo Flooring Manufacturer BambooIndustry.com Introduces Its Bamboo Flooring Promotion for 2015 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Atore, Inc. Releasing the First Birthday Portal 2
Other TagsOther Tags